# Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

> **NCT06203821** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Aram Hezel** · enrollment: 25 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** NP137

## Key facts

- **NCT ID:** NCT06203821
- **Lead sponsor:** Aram Hezel
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-05-30
- **Final completion:** 2032-09-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203821, "Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06203821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*